Ruxolitinib, the JAK1/2 inhibitor, is currently observed to be effective in the HLH mouse model (Maschalidi et al., 2016; Albeituni et al., 2019), whose role in HLH is thought to extinguish inflammatory factor storms by inhibiting the JAK-STAT pathway. Here, JAK1 is linked to hemophagocytic syndrome.